The study analyzed the cost-effectiveness of factor IX gene therapy in patients with severe hemophilia B, providing insights for clinical practice and economic decision-making.
In this issue of Blood, Boulos et al(1) analyze the cost-effectiveness of factor IX gene therapy in patients with severe hemophilia B, in a microsimulation Markov model.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
